Development plan

$2M pre-seed funds TFT de-risk, the impedance gate, driver v1, alpha chip, and first autonomous experiment. Seed funds manufacturing scale, patient samples, autonomous screens, paying AI customers, and de-risking token-based pricing. Series A closes H2 2028.

Usage-based token based pricing. 10+ AI and frontier-lab customers. First autonomous-screens for personalized medicine from discovery to patient dosing. Frontier models running autonomous biological data generation at scale, calling Rivulet as the physical execution layer.